A pharmacogenomics primer

Journal of Clinical Pharmacology

Volumn 47, Issue 9, 2007, Pages 1087-1103

  Court, Michael H ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Pharmacogenetics; Pharmacogenomics; Primer; Review

Indexed keywords

ATOMOXETINE; AZATHIOPRINE; DRUG METABOLIZING ENZYME; IRINOTECAN; MERCAPTOPURINE; THIOPURINE METHYLTRANSFERASE; WARFARIN;

DRUG EFFICACY; DRUG METABOLISM; DRUG RESEARCH; ENZYME POLYMORPHISM; GENE DELETION; GENE DUPLICATION; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC MARKER; HAPLOTYPE; HUMAN; INDEL MUTATION; MICROSATELLITE MARKER; NOMENCLATURE; PHARMACOGENOMICS; REVIEW; RNA SPLICING; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSCRIPTION REGULATION; UNTRANSLATED REGION;

ALLELES; GENETIC MARKERS; GENOME, HUMAN; HUMANS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; TERMINOLOGY AS TOPIC;

EID: 50249142263     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270007303768     Document Type: Review

References (69)

1. Meyer UA. Pharmacogenetics-five decades of therapeutic lessons from genetic diversity. Nat Rev Genet. 2004;5:669-676.
2. 2. Andersson T, Flockhart DA, Goldstein DB, et al. Drug-metabolizing enzymes: evidence for clinical utility of pharmacogenomic tests. Clin Pharmacol Ther. 2005;78:559-581. (Pubitemid 41773633)
3. Roses AD. Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet. 2004;5:645-656.
4. 4. Bartlett JM. Pharmacodiagnostic testing in breast cancer: focus on HER2 and trastuzumab therapy. Am J Pharmacogenomics. 2005;5:303-315. (Pubitemid 41425608)
5. Southan C. Has the yo-yo stopped? An assessment of human protein-coding gene number. Proteomics. 2004;4:1712-17263
6. 6. Torroni A, Achilli A, Macaulay V, Richards M, Bandelt HJ. Harvesting the fruit of the human mtDNA tree. Trends Genet. 2006;22:339-345. (Pubitemid 43794927)
7. Amacher DE. Drug-associated mitochondrial toxicity and its detection. Curr Med Chem. 2005;12:1829-1839.
8. 8. Conti E, Izaurralde E. Nonsense-mediated mRNA decay: molecular insights and mechanistic variations across species. Curr Opin Cell Biol. 2005; 17:316-325. (Pubitemid 40719923)
9. 9. Furuta T, Ohashi K, Kamata T, et al. Effect of genetic differences in omeprazole metabolism on cure rates for Helicobacter pylori infection and peptic ulcer. Ann Intern Med. 1998;129:1027-1030. (Pubitemid 29005826)
10. 10. Goldstein JA, Ishizaki T, Chiba K, et al. Frequencies of the defective CYP2C19 alleles responsible for the mephenytoin poor metabolizer phenotype in various Oriental, Caucasian, Saudi Arabian and American black populations. Pharmacogenetics. 1997;7:59-64. (Pubitemid 27153320)
11. Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005; 20:153-167.
12. 12. De Morais SM, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese. Mol Pharmacol. 1994;46:594-598. (Pubitemid 24334747)
13. 13. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A "silent" polymorphism in the MDRl gene changes substrate specificity. Science. 2007;315:525-528. (Pubitemid 46175758)
14. Qiu LO, Linder MW, Antonino-Green DM, Valdes R Jr. Suppression of cytochrome P450 2E1 promoter activity by interferon-gamma and loss of response due to the -71G>T nucleotide polymorphism of the CYP2E1*7B allele. J Pharmacol Exp Ther. 2004;308:284-288.
15. Gonzalez FJ. The 2006 Bernard B. Brodie Award Lecture. Cyp2e1. Drag Metab Dispos. 2007; 35:1-8.
16. 16. Tazi J, Durand S, Jeanteur P. The spliceosome: a novel multifaceted target for therapy. Trends Biochem Sci. 2005;30:469-478. (Pubitemid 41033243)
17. Jurica MS, Moore MJ. Pre-mRNA splicing: awash in a sea of proteins. Mol Cell. 2003;12:5-14.
18. 18. Rogan PK, Svojanovsky S, Leeder JS. Information theory-based analysis of CYP2C19, CYP2D6 and CYP3A5 splicing mutations. Pharmacogenetics. 2003;13:207-218. (Pubitemid 36543393)
19. 19. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet. 2001;27:383-391. (Pubitemid 32268418)
20. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics. 2001;11:773-779.
21. Pullmann R Jr, Abdelmohsen K, Lal A, Martindale JL, Ladner RD, Gorospe M. Differential stability of thymidylate synthase 3′untranslated region polymorphic variants regulated by AUF1. Biol Chem. 2006;281:23456-23463.
22. Kim VN, Nam JW. Genomics of microRNA. Trends Genet. 2006;22:165-173.
23. 23. Clop A, Marcq F, Takeda H, et al. A mutation creating a potential illegitimate microRNA target site in the myostatin gene affects muscularity in sheep. Nat Genet. 2006;38:813-818. (Pubitemid 43980603)
24. 24. Chen K, Rajewsky N. Natural selection on human microRNA binding sites inferred from SNP data. Nat Genet. 2006;38: 1452-1456. (Pubitemid 44837570)
25. 25. Nagar S, Blanchard RL. Pharmacogenetics of uridine diphosphoglucuronosyltransferase (UGT) 1A family members and its role in patient response to irinotecan. Drug Metab Rev. 2006; 38:393-409. (Pubitemid 44167197)
26. Guillemette C. Pharmacogenomics of human UDP-glucuronosyltransferase enzymes. Pharmacogenomics J. 2003;3:136-158.
27. O'Dwyer PJ, Catalano RB. Uridine diphosphate glucuronosyltransferase (UGT) 1A1 and irinotecan: practical pharmacogenomics arrives in cancer therapy. J Clin Oncol. 2006;24: 4534-4538.
28. Mehra R, Murren J, Chung G, Smith B, Psyrri A. Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism. Clin Colorectal Cancer. 2005; 5:61-64.
29. Innocenti F, Ratain MJ. Irinotecan treatment in cancer patients with UGT1A1 polymorphisms. Oncology (Williston Park). 2003; 17:52-55. 7 30. Ando Y, Saka H, Ando M, et al. Polymorphisms of UDPglucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res. 2000;60:6921-6926.
30. Toffoli G, Cecchin E, Corona G, et al. The role of UGT1A1 *28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer. J Clin Oncol. 2006;24:3061-3068.
31. 32. Innocenti F, Ratain MJ. Pharmacogenetics of irinotecan: clinical perspectives on the utility of genotyping. Pharmacogenomics. 2006;7:1211-1221. (Pubitemid 46024184)
32. 33. Maitland ML, Vasisht K, Ratain MJ. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy? Trends Pharmacol Sci. 2006;27:432-437. (Pubitemid 44051569)
33. Invader UGT1Al molecular assay for irinotecan toxicity. A genetic test for an increased risk of toxicity from the cancer chemotherapy drug irinotecan (Camptosar). Med Lett Drugs Ther. 2006;48:39-40.
34. Ratain MJ. From bedside to bench to bedside to clinical practice: an Odyssey with irinotecan. Clin Cancer Res. 2006;12: 1658-1660.
35. 36. Ingelman-Sundberg M, Oscarson M, McLellan RA. Polymorphic human cytochrome P450 enzymes: an opportunity for individualized drug treatment. Trends Pharmacol Sci. 1999; 20:342-349. (Pubitemid 29366813)
36. 37. Dalen P, Dahl ML, Bernai Ruiz ML, Nordin J, Bertilsson L. 10-Hydroxylation of nortriptyline in white persons with 0,1, 2, 3, and 13 functional CYP2D6 genes. Clin Phamiacol Ther. 1998;63:444-452. (Pubitemid 28214968)
37. 38. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. Frequent distribution of ultrarapid metabolizers of debrisoquine in an Ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther. 1996;278:441-446. (Pubitemid 27167124)
38. 39. Oscarson M, McLellan RA, Gullsten H, et al. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population. FEBS Lett. 1999;448: 105-110. (Pubitemid 29153723)
39. 40. Park J, Chen L, Ratnashinge L, et al. Deletion polymorphism of UDP-glucuronosyltransferase 2B17 and risk of prostate cancer in African American and Caucasian men. Cancer Epidemiol Biomarkers Prev. 2006;15:1473-1478. (Pubitemid 44299318)
40. 41. Lazarus P, Zheng Y, Aaron Runkle E, Muscat JE, Wiener D. Genotype-phenotype correlation between the polymorphic UGT2B17 gene deletion and NNAL glucuronidation activities in human liver microsomes. Pharmacogenet Genomics. 2005;15: 769-778. (Pubitemid 41531726)
41. 42. Hebbring SJ, Adjei AA, Baer JL, et al. Human SULT1A1 gene: copy number differences and functional implications. Hum Mol Genet. 2007;16:463-470. (Pubitemid 46522610)
42. 43. Christiansen L, Brasch-Andersen C, Bathum L, Kruse TA, Christensen K. A longitudinal study of the effect of GSTT1 and GSTM1 gene copy number on survival. Mech Ageing Dev. 2006;127:597-599. (Pubitemid 43729537)
43. 44. Buckley PG, Mantripragada KK, Piotrowski A, Diaz de Stahl T, Dumanski JP. Copy-number polymorphisms: mining the tip of an iceberg. Trends Genet. 2005;21:315-317. (Pubitemid 40726385)
44. Burk O, Tegude H, Koch I, et al. Molecular mechanisms of polymorphic CYP3A7 expression in adult human liver and intestine. J Biol Chem. 2002;277:24280-24288.
45. Sim SC, Edwards RJ, Boobis AR, Ingelman-Sundberg M. CYP3A7 protein expression is high in a fraction of adult human livers and partially associated with the CYP3A7*1C allele. Pharmacogenet Genomics. 2005;15:625-631.
46. Williams JA, Ring BJ, Cantrell VE, et al. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7. Drug Metab Dispos. 2002;30:883-891.
47. den Dünnen JT, Antonarakis SE. Mutation nomenclature extensions and suggestions to describe complex mutations: a discussion. Hum Mutat. 2000;15:7-12.
48. den Dünnen JT, Antonarakis SE. Nomenclature for the description of human sequence variations. Hum Genet. 2001;109:121-124.
49. den Dünnen JT, Paalman MH. Standardizing mutation nomenclature: why bother? Hum Mutat. 2003;22:181-182.
50. Wain HM, Bruford EA, Lovering RC, Lush MJ, Wright MW, Povey S. Guidelines for human gene nomenclature. Genomics. 2002;79:464-470.
51. 52. Xu CF, Lewis KF, Yeo AJ, et al. Identification of a pharmacogenetic effect by linkage disequilibrium mapping. Pharmacogenomics J. 2004;4:374-378. (Pubitemid 39600054)
52. 53. Steemers FJ, Gunderson KL. Whole genome genotyping technologies on the BeadArray platform. Biotechnol J. 2007;2:41-49. (Pubitemid 46738887)
53. 54. Klein RJ, Zeiss C, Chew EY, et al. Complement factor H polymorphism in age-related macular degeneration. Science. 2005;308:385-389. (Pubitemid 40530070)
54. 55. Dewan A, Liu M, Hartman S, et al. HTRA1 promoter polymorphism in wet age-related macular degeneration. Science. 2006;314:989-992. (Pubitemid 44749943)
55. 56. Bennett ST, Barnes C, Cox A, Davies L, Brown C. Toward the 1,000 dollars human genome. Pharmacogenomics. 2005;6:373-382. (Pubitemid 40916360)
56. 57. Gunderson KL, Kuhn KM, Steemers FJ, Ng P, Murray SS, Shen R. Whole-genome genotyping of haplotype tag single nucleotide polymorphisms. Pharmacogenomics. 2006;7:641-648. (Pubitemid 43891420)
57. Consortium. IH. A haplotype map of the human genome. Nature. 2005;437:1299-1320.
58. Ahmadi KR, Weale ME, Xue ZY, et al. A single-nucleotide polymorphism tagging set for human drug metabolism and transport. Nat Genet. 2005; 37:84-89.
59. 60. Conrad DF, Jakobsson M, Coop G, et al. A worldwide survey of haplotype variation and linkage disequilibrium in the human genome. Nat Genet. 2006;38:1251-1260. (Pubitemid 44646287)
60. Zheng CJ, Han LY, Xie B, et al. PharmGED: Pharmacogenetic Effect Database. Nucleic Acids Res. 2007;35:D794-D799.
61. Hodge AE, Altman RB, Klein TE. The PharmGKB: integration, aggregation, and annotation of pharmacogenomic data and knowledge. Clin Pharmacol Ther. 2007;81:21-24.
62. 63. Moroni M, Veronese S, Benvenuti S, et al. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol. 2005;6:279-286. (Pubitemid 40590264)
63. Esteva FJ, Cheli CD, Fritsche H, et al. Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumabbased therapies. Breast Cancer Res. 2005;7:R436-R443.
64. Evans WE. Pharmacogenetics of thiopurine S-methyltransferase and thiopurine therapy. Ther Drug Monit. 2004;26:186-191.
65. 66. Iyer L, Das S, Janisch L, et al. UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity. Pharmacogenomics J. 2002;2:43-47. (Pubitemid 34982202)
66. 67. Vercauteren J, Vandamme AM. Algorithms for the interpretation of HIV-I genotypic drug resistance information. Antiviral Res. 2006;71:335-342. (Pubitemid 44223769)
67. Gardiner SJ, Begg EJ. Pharmacogenetic testing for drug metabolizing enzymes: is it happening in practice? Pharmacogenet Genomics. 2005;15:365-369.
68. 69. Fargher EA, Tricker K, Newman W, et al. Current use of pharmacogenetic testing: a national survey of thiopurine methyltransferase testing prior to azathioprine prescription. J. Clin Pharm Ther. 2007;32:187-195. (Pubitemid 46449703)
69. 70. Haga SB, Thummel KE, Burke W. Adding pharmacogenetics information to drug labels: lessons learned. Pharmacogenet Genomics. 2006;16:847-854. (Pubitemid 44772802)